Recently, cancer immunotherapy has received attention as a viable solution for the treatment of refractory tumors. However, it still has clinical limitations in its treatment efficacy due to inter-patient tumor heterogeneity and immunosuppressive tumor microenvironment (TME). In this study, we demonstrated the triggering of anti-cancer immune responses by a combination of irreversible electroporation (IRE) and a stimulator of interferon genes (STING) agonist. Optimal electrical conditions inducing damage-associated molecular patterns (DAMPs) by immunogenic cell death (ICD) were determined through in vitro 2D and 3D cell experiments. In the in vivo syngeneic lung cancer model, the combination of IRE and STING agonists demonstrated significant tumor growth inhibition. We believe that the combination strategy of IRE and STING agonists has potential for effective cancer immunotherapy.
Bibliographical noteFunding Information:
Funding: This work was supported by the National Research Foundation (NRF) of Korea. The grant was funded by the Ministry of Science and ICT (MSIT), Republic of Korea (2018R1C1B6001120, 2020M2D9A3094208, 2020R1A2C2004530, and 2020R1A2B5B03002344).
All Science Journal Classification (ASJC) codes
- Cancer Research